Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

MDxHealth announces results from its pivotal clinical validation study for ConfirmMDx for Prostate Cancer


Thursday, 15 May 2014 02:00am EDT 

MDxHealth SA:Announces results from its pivotal clinical validation study for ConfirmMDx for Prostate Cancer.DOCUMENT (Detection of Occult Cancer Using Methylated Events in Negative Tissue) validation study validates the ConfirmMDx for Prostate Cancer test as most significant predictor of risk for presence of occult cancer above any other risk factor used to guide decision for repeat biopsy.Study further validates that ConfirmMDx test provides actionable information to improve patient risk stratification men and aid urologists to differentiate prostate-cancer-free men from those who may harbor undetected prostate cancer. 

Company Quote

4.08
0.135 +3.42%
9:53am EST